Page 614 - Cardiac Nursing

0
0
009
1:4
3 P
3 P
1:4
xd
3
Pa
55
5-5
5-5
55
M
A
94.
94.
A
p
p
p
t
Pa
M
xd
q
q
q
g
p
24_
24_
p
t
ara
ara
LWB
LWB
LWBK340-c24_ pp555-594.qxd 30/06/2009 01:43 PM Page 590 Aptara
K34
0-c
0-c
K34
6/2
90
3
g
90
g
e 5
e 5
0/0
6/2
009
0/0
3
590 PA R T I V / Pathophysiology and Management of Heart Disease
31. Ezekowitz, J., McAlister, F. A., Humphries, K. H., et al. (2004). 52. Nielsen, O. W., McDonagh, T. A., Robb, S. D., et al. (2003). Retro-
The association among renal insufficiency, pharmacotherapy, and spective analysis of the cost-effectiveness of using plasma brain natriuretic
outcomes in 6,427 patients with heart failure and coronary artery peptide in screening for left ventricular systolic dysfunction in the gen-
disease. Journal of the American College of Cardiology, 44(8), eral population. Journal of American College of Cardiology, 41(1),
1587–1592. 113–120.
32. Owan, T. E., Hodge, D. O., Herges, R. M., et al. (2006). Secular trends 53. Vasan, R. S., Beiser, A., D’Agostino, R. B., et al. (2003). Plasma homo-
in renal dysfunction and outcomes in hospitalized heart failure patients. cysteine and risk for congestive heart failure in adults without prior my-
Journal of Cardiac Failure, 12(4), 257–262. ocardial infarction. JAMA, 289(10), 1251–1257.
33. Mann, J. F., Sheridan, P., McQueen, M. J., et al. (2008). Homocysteine 54. Aaronson, K. D., & Sackner-Bernstein, J. (2006). Risk of death associ-
lowering with folic acid and B vitamins in people with chronic kidney ated with nesiritide in patients with acutely decompensated heart failure.
6
6
disease—Results of the renal Hope-2 study. Nephrology Dialysis Trans- JAMA, 296(12), 1465–1466.
plantation, 23(2), 645–653. 55. Mosterd, A., Cost, B., Hoes, A. W., et al. (2001). The prognosis of heart
34. Mann, D. L. (2006). Heart failure: Beyond practice guidelines. Texus Di- failure in the general population: The Rotterdam Study. European Heart
aliasis Heart Institute Journal, 33(2), 201–203. Journal, 22(15), 1318–1327.
35. Mann, D. L. (2004). Basic mechanisms of left ventricular remodeling: 56. Roger, V. L., Weston, S. A., Redfield, M. M., et al. (2004). Trends in
The contribution of wall stress. Journal of Cardiac Failure, 10(6, Suppl.), heart failure incidence and survival in a community-based population.
S202–S206. JAMA, 292(3), 344–350.
36. De Keulenaer, G. W., & Brutsaert, D. L. (2007). Diastolic heart failure: 57. Mozaffarian, D., Anker, S. D., Anand, I., et al. (2007). Prediction of
A separate disease or selection bias? Progress in Cardiovascular Disease, mode of death in heart failure: The Seattle Heart Failure Model. Circu-
6
49(4), 275–283. lation, 116(4), 392–398.
6
37. Bhatia, R. S., Tu, J. V., Lee, D. S., et al. (2006). Outcome of heart fail- 58. Ammar, K. A., Jacobsen, S. J., Mahoney, D. W., et al. (2007). Preva-
ure with preserved ejection fraction in a population-based study. New lence and prognostic significance of heart failure stages: Application of
England Journal of Medicine, 355(3), 260–269. the American College of Cardiology/American Heart Association heart
38. Sanderson, J. E., & Tse, T. F. (2003). Heart failure: A global disease re- failure staging criteria in the community. Circulation, 115(12),
quiring a global response. Heart, 89(6), 585–586. 1563–1570.
39. Lang, R. M., Bierig, M., Devereux, R. B., et al. (2005). Recommenda- 59. Parkash, R., Stevenson, W. G., Epstein, L. M., et al. (2006). Predicting
tions for chamber quantification: A report from the American Society of early mortality after implantable defibrillator implantation: A clinical risk
Echocardiography’s Guidelines and Standards Committee and the score for optimal patient selection. American Heart Journal, 151(2),
Chamber Quantification Writing Group, developed in conjunction with 397–403.
the European Association of Echocardiography, a branch of the Euro- 60. Linseman, J. V., & Bristow, M. R. (2003). Drug therapy and heart fail-
7
7
pean Society of Cardiology. Journal of the American Society of Echocardio- ure prevention. Circulation, 107(9), 1234–1236.
graphy, 18(12), 1440–1463. 61. Fuster, V., Gersh, B. J., Giuliani, E. R., et al. (1981). The natural history
40. Kitzman, D. W., Little, W. C., Brubaker, P. H., et al. (2002). Patho- of idiopathic dilated cardiomyopathy. American Journal of Cardiology,
7
physiological characterization of isolated diastolic heart failure in com- 47(3), 525–531.
7
parison to systolic heart failure. JAMA, 288(17), 2144–2150. 62. Al-Khadra, A. S., Salem, D. N., Rand, W. M., et al. (1998). Warfarin an-
41. Brucks, S., Little, W. C., Chao, T., et al. (2005). Contribution of left ven- ticoagulation and survival: A cohort analysis from the studies of left ven-
tricular diastolic dysfunction to heart failure regardless of ejection frac- tricular dysfunction. Journal of the American College of Cardiology, 31(4),
tion. American Journal of Cardiology, 95(5), 603–606. 749–753.
42. Shahar, E., Whitney, C. W., Redline, S., et al. (2001). Sleep-disordered 63. Dries, D. L., Domanski, M. J., Waclawiw, M. A., et al. (1997). Effect of
breathing and cardiovascular disease: Cross-sectional results of the Sleep antithrombotic therapy on risk of sudden coronary death in patients with
Heart Health Study. American Journal of Respiratory and Critical Care congestive heart failure. American Journal of Cardiology, 79(7), 909–913.
Medicine, 163(1), 19–25. 64. Lindenfeld, J., Feldman, A. M., Saxon, L., et al. (2007). Effects of car-
43. Patel, J., & Heywood, J. T. (2007). Mode of death in patients with sys- diac resynchronization therapy with or without a defibrillator on survival
tolic heart failure. Journal of Cardiovascular Pharmacology and Therapeu- and hospitalizations in patients with New York Heart Association class
tics, 12(2), 127–136. IV heart failure. Circulation, 115(2), 204–212.
44. Bates, B. (1991). A guide to physical examination and history taking (5th 65. Auricchio, A., Metra, M., Gasparini, M., et al. (2007). Long-term sur-
ed.). Philadelphia: J.B. Lippincott Company. vival of patients with heart failure and ventricular conduction delay
45. Angeja, B. G., & Grossman, W. (2003). Evaluation and management of treated with cardiac resynchronization therapy. The American Journal of
7
diastolic heart failure. Circulation, 107(5), 659–663. Cardiology, 99(2), 232–238.
7
46. Glassberg, H., Kirkpatrick, J., & Ferrari, V. A. (2008). Imaging studies 66. Mehta, P. A., Dubrey, S. W., McIntyre, H. F., et al. (2008). Mode of
in patients with heart failure: Current and evolving technologies. Criti- death in patients with newly diagnosed heart failure in the general pop-
cal Care Medicine, 36(1, Suppl.), S28–S39. ulation. European Journal of Heart Failure, 10(11), 1108–1116.
6
6
47. Velazquez-Cecena, J. L., Sharma, S., Nagajothi, N., et al. (2008). Left 67. Miller, L. W. (1998). Listing criteria for cardiac transplantation: Results
ventricular end diastolic pressure and serum brain natriuretic peptide lev- of an American Society of Transplant Physicians—National Institutes of
6
6
els in patients with abnormal impedance cardiography parameters. Health conference. Transplantation, 66(7), 947–951.
Archives of Medical Research, 39(4), 408–411. 68. Effects of enalapril on mortality in severe congestive heart failure. Results
48. Van Mieghem, C. A. G., McFadden, E. P., de Feyter, P. J., et al. (2006). of the Cooperative North Scandinavian Enalapril Survival Study (CON-
Noninvasive detection of subclinical coronary atherosclerosis coupled SENSUS). The CONSENSUS Trial Study Group. (1987). New England
with assessment of changes in plaque characteristics using novel invasive Journal of Medicine, 316(23), 1429–1435.
6
6
imaging modalities: The integrated biomarker and imaging 69. Effect of enalapril on survival in patients with reduced left ventricular
7
study (IBIS). Journal of the American College of Cardiology, 47(6), ejection fractions and congestive heart failure. The SOLVD Investigators.
7
1134–1142. (1991). New England Journal of Medicine, 325(5), 293–302.
49. Anand, I. S., Kuskowski, M. A., Rector, T. S., et al. (2005). Anemia and 70. Howard, P. A., Cheng, J. W. M., Crouch, M. A., et al. (2006). Drug ther-
change in hemoglobin over time related to mortality and morbidity in apy recommendations from the 2005 ACC/AHA guidelines for treatment
patients with chronic heart failure: Results from Val-HeFT. Circulation, of chronic heart failure. The Annals of Pharmacotherapy, 40(9),
112(8), 1121–1127. 1607–1616.
50. Maisel, A. S., Koon, J., Krishnaswamy, P., et al. (2001). Utility of B- 71. Shibata, M. C., Tsuyuki, R. T., & Wiebe, N. (2008). The effects of an-
natriuretic peptide as a rapid, point-of-care test for screening patients giotensin-receptor blockers on mortality and morbidity in heart failure:
undergoing echocardiography to determine left ventricular dysfunction. A systematic review. International Journal of Clinical Practice, 62(9),
American Heart Journal, 141(3), 367–374. 1397–1402.
51. Lubien, E., DeMaria, A., Krishnaswamy, P., et al. (2002). Utility of B-na- 72. Aronow, W. S. (2003). Epidemiology, pathophysiology, prognosis, and
triuretic peptide in detecting diastolic dysfunction: Comparison with treatment of systolic and diastolic heart failure in elderly patients. Heart
Doppler velocity recordings. Circulation, 105(5), 595–601. Disease, 5(4), 279–294.